893755-01-6

Usage

Uses

Used in Pharmaceutical Industry:
1-[2-(4-methoxyphenyl)ethyl]piperidin-4-ylmethylamine is used as a psychoactive substance for research purposes in the pharmaceutical industry. Its SSRA and stimulant properties make it a compound of interest for studying the effects and potential applications of similar drugs in the treatment of various conditions related to serotonin levels and mood regulation.
Used in Research and Development:
In the field of research and development, 1-[2-(4-methoxyphenyl)ethyl]piperidin-4-ylmethylamine is used as a chemical reference and a starting point for the synthesis of new compounds with potential therapeutic applications. Its unique structure and activity as an SSRA and stimulant provide valuable insights into the design and development of novel drugs targeting the serotonin system.
Used in Forensic Toxicology:
1-[2-(4-methoxyphenyl)ethyl]piperidin-4-ylmethylamine, being a designer drug, is also used as a reference compound in forensic toxicology. It helps in the identification and analysis of similar substances found in cases involving drug abuse or intoxication, aiding in the investigation and prosecution of related crimes.

Upstream product

• 71207-29-9 N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine 
• 7144-05-0 4-Aminomethylpiperidine 
• 14425-64-0 4-methoxyphenethyl bromide 

Downstream Products

• 1029643-61-5 N-({1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}methyl)-2-methyl-2H-indazole-3-carboxamide hydrochloride 
• 1029644-03-8 N-((1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)methyl)-2-methyl-2H-indazole-3-carboxamide 
• 1029643-81-9 ((1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)methyl)formamide 

Relevant academic research and scientific papers

Targeting Serotonin 2A and Adrenergic α1 Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one Derivatives

Glaucoma affects millions of people worldwide and causes optic nerve damage and blindness. The elevation of the intraocular pressure (IOP) is the main risk factor associated with this pathology, and decreasing IOP is the key therapeutic target of current pharmacological treatments. As potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1) linked to the regulation of aqueous humour dynamics. Herein we describe the design, synthesis, and pharmacological profiling of a series of novel bicyclic and tricyclic N2-alkyl-indazole-amide derivatives. This study identified a 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivative with potent serotonin 2A receptor antagonism, >100-fold selectivity over other serotonin subtype receptors, and high affinity for the α1 receptor. Moreover, upon local administration, this compound showed superior ocular hypotensive action in vivo relative to the clinically used reference compound timolol.

Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders

Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3β (GSK-3β) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3β inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3β. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3β inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3β inhibitors as new tools in the development of new treatments for mood disorders.

NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1 H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.